-

New Assessment Identifies the High-Risk Functions Within Pharma That Are Least Prepared for Challenges Ahead

Sales Rep Training, Forecasting, Competitive Intelligence, Patient Support Services, and KOL Relationship Management among the Functions within the Pharmaceutical Commercial Model Most in Need of Change During and Post-Pandemic

original The dashboard reflects the impact of COVID-19 on life science companies' commercial capabilities. (Graphic: Business Wire)

The dashboard reflects the impact of COVID-19 on life science companies' commercial capabilities. (Graphic: Business Wire)

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity Life Sciences, a leader in global life sciences solutions, announced today the availability of a new TGaS benchmarking assessment that identifies the high-risk functions within pharma that are least prepared for challenges generated by the COVID-19 pandemic.

Sales rep training, forecasting, competitive intelligence, patient support services and KOL relationship management are among the highest risk functions that need to consider significant evolution to adjust to a current and post-pandemic world.

“The COVID-19 crisis has all of us engaged with the U.S. healthcare system thinking about how the future may look different than our collective past,” said Gary McWalters, President of TGaS Advisors, a Division within Trinity. “With forward-looking ideas in mind, TGaS has considered the most likely changes within the pharmaceutical commercial model and assessed which commercial operations functional areas are most likely to be least prepared from a capabilities perspective for the challenges that lie ahead.”

The dashboard can be viewed: Impact of COVID-19 on Commercial Capabilities by Functional Area.

About Trinity Life Sciences

Trinity Life Sciences is a trusted strategic partner, providing evidence-based solutions for the life sciences. With over 20 years of experience, Trinity is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit trinitylifesciences.com.

Contacts

For more information:
Elizabeth Marshall
Trinity Life Sciences
781-577-6376
emarshall@trinitylifesciences.com

Industry:

Trinity Life Sciences

Release Versions
English
Hashtags
#highriskfunctions
#tgasadvisors
#trinitylifesciences

Contacts

For more information:
Elizabeth Marshall
Trinity Life Sciences
781-577-6376
emarshall@trinitylifesciences.com

More News From Trinity Life Sciences

Trinity Appoints Scott Evangelista as CEO to Lead Next Chapter

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity, a global leader in technology-enabled commercialization solutions for the life sciences industry, today announced Scott Evangelista has been appointed Chief Executive Officer, succeeding Leslie Orne who is stepping down after three years as CEO and over 24 years with the company. Ms. Orne will transition to the role of Senior Advisor and serve as a member of Trinity’s Board of Directors. Over her distinguished tenure, Ms. Orne helped guide Trinity’s evo...

GSK, Amgen and AstraZeneca Lead the Pack in Trinity’s 2025 Digital Marketing Competency Report

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity, a leader in global life sciences commercialization, today announced the release of its 5th Annual TGaS Digital Marketing Competency Report, a three-part series benchmarking the digital marketing presence of more than 150 biopharma brands. The 2025 edition reveals a significant leap forward in the industry’s digital sophistication, with a 19% increase in Proficient brands and a surge of innovation in patient engagement strategies. The report ranks each b...

Trinity Expands Global Footprint with Acquisition of EVERSANA’s APACME Advisory Services

WALTHAM, Mass.--(BUSINESS WIRE)--Trinity, a leader in global life sciences commercialization solutions and recognized for being a strategic, tech-enabled commercialization company that empowers pharma, biotech, and medtech organizations to advance medical innovations, announced today the acquisition of EVERSANA’s advisory services operation in Asia-Pacific and the Middle East (APACME). The strategic acquisition will transition EVERSANA’s advisory services operation in APACME to Trinity, further...
Back to Newsroom